CervoMed wins U.S. patent allowance for neflamapimod use in pure Lewy body dementia into 2042

CervoMed Inc.

CervoMed Inc.

CRVO

0.00
  • CervoMed received a USPTO notice of allowance for a US patent covering neflamapimod use in “pure” dementia with Lewy bodies patients.
  • The patent targets DLB patients without substantial Alzheimer’s-like tau pathology, defined by plasma pTau levels or brain imaging.
  • Intellectual property protection is expected to run into 2042, with potential extension through patent term extension.
  • Neflamapimod has completed a Phase 2b RewinD-LB trial; Phase 3 timing depends on partnership or additional financing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606180700PRIMZONEFULLFEED9749054) on June 18, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.